Janux Therapeutics annual current ratio
2020
2021
2022
2023
2024
2025
Janux Therapeutics Current Ratio Growth & History (JANX)
Janux Therapeutics's current ratio was 39.04 for fiscal 2025.
View full Janux Therapeutics company overviewJanux Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 39.04 | −20.17 | −34.06% |
| 2024 | 2024-12-31 | 59.21 | 32.41 | +120.94% |
| 2023 | 2023-12-31 | 26.80 | 6.66 | +33.06% |
| 2022 | 2022-12-31 | 20.14 | −9.32 | −31.64% |
| 2021 | 2021-12-31 | 29.46 | 24.41 | +483.47% |
| 2020 | 2020-12-31 | 5.05 | — | — |
Janux Therapeutics quarterly current ratio
Q4.20
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 16.35 | −30.69 | −65.24% |
| Q1 2026 | 2026-03-31 | 17.01 | −41.46 | −70.91% |
| Q4 2025 | 2025-12-31 | 39.04 | −20.17 | −34.06% |
| Q3 2025 | 2025-09-30 | 35.86 | −2.94 | −7.57% |
| Q2 2025 | 2025-06-30 | 47.03 | −10.30 | −17.97% |
| Q1 2025 | 2025-03-31 | 58.47 | −3.62 | −5.82% |
| Q4 2024 | 2024-12-31 | 59.21 | 32.41 | +120.94% |
| Q3 2024 | 2024-09-30 | 38.80 | 14.26 | +58.08% |
| Q2 2024 | 2024-06-30 | 57.34 | 40.06 | +231.89% |
| Q1 2024 | 2024-03-31 | 62.09 | 42.14 | +211.28% |
| Q4 2023 | 2023-12-31 | 26.80 | 6.66 | +33.06% |
| Q3 2023 | 2023-09-30 | 24.55 | 3.47 | +16.44% |
| Q2 2023 | 2023-06-30 | 17.28 | −10.28 | −37.31% |
| Q1 2023 | 2023-03-31 | 19.95 | −9.19 | −31.55% |
| Q4 2022 | 2022-12-31 | 20.14 | −9.32 | −31.64% |
| Q3 2022 | 2022-09-30 | 21.08 | −10.16 | −32.52% |
| Q2 2022 | 2022-06-30 | 27.56 | −15.53 | −36.04% |
| Q1 2022 | 2022-03-31 | 29.14 | — | — |
| Q4 2021 | 2021-12-31 | 29.46 | 24.41 | +483.47% |
| Q3 2021 | 2021-09-30 | 31.24 | — | — |
| Q2 2021 | 2021-06-30 | 43.09 | — | — |
| Q4 2020 | 2020-12-31 | 5.05 | — | — |
Janux Therapeutics current ratio trends
Over the last five fiscal years, Janux Therapeutics's current ratio increased from 5.05 to 39.04, a change of 33.99. The latest reported quarter, Q2 2026, shows 16.35.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Janux Therapeutics source filings ↗